Health
Phase I/II trial findings support use of CoronaVac vaccine in older individuals – News-Medical.Net
Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and…
Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
CoronaVac is an inactivated SARS-CoV-2 vaccine developed by Chinese pharmaceutical company Sinovac Life Sciences based in Beijing, China.
Writing in The Lancet Infectious…
-
Business21 hours agoEvery ASX 200 sector closed in the red last week. Here’s why
-
Noosa News24 hours agoGT3 driver Renee Gracie on sexism in motorsport and how OnlyFans turned her career around
-
Noosa News20 hours agoFervor Wines label started during pandemic keeps father and son close
-
Business24 hours agoHow to build a balanced ASX portfolio for the next decade